Company Overview and News

 
National General Holdings Corp. to Present at the 2018 KBW Insurance Conference on Thursday, September 6, 2018

2018-08-29 globenewswire
NEW YORK, Aug. 29, 2018 (GLOBE NEWSWIRE) -- National General Holdings Corp. (NASDAQ:NGHC) announced today that it will present at the 2018 Keefe, Bruyette & Woods Insurance Conference which will be held in New York, New York on September 5 and 6, 2018. National General’s Chief Financial Officer Mike Weiner is scheduled to present at 9:20 A.M. ET on Thursday, September 6, 2018.
NGHCP NGHCO NGHCN NGHC NGHCZ

 
National General Holdings Corp 2018 Q2 - Results - Earnings Call Slides

2018-08-08 seekingalpha
The following slide deck was published by National General Holdings Corp in conjunction with their 2018 Q2 earnings call.
NGHCP NGHCO NGHCN NGHC NGHCZ

 
National General Holdings Corp. (NGHC) CEO Barry Karfunkel on Q2 2018 Results - Earnings Call Transcript

2018-08-07 seekingalpha
National General Holdings Corp. (NASDAQ:NGHC) Q2 2018 Earnings Conference Call August 7, 2018 9:30 AM ET
NGHCP NGHCO NGHCN NGHC MS NGHCZ

1
National General Holdings (NGHC) Beats Q2 Earnings and Revenue Estimates

2018-08-06 zacks
National General Holdings (NGHC - Free Report) just came out with quarterly earnings of $0.54 per share, beating the Zacks Consensus Estimate of $0.50 per share. This compares to earnings of $0.11 per share a year ago. These figures are adjusted for non-recurring items.
NGHCP NGHCO NGHCN KRNT AMT NGHC BRKS NGHCZ GTLS

 
National General Holdings Corp. Reports Second Quarter 2018 Results

2018-08-06 globenewswire
NEW YORK, Aug. 06, 2018 (GLOBE NEWSWIRE) -- National General Holdings Corp. (Nasdaq:NGHC) today reported second quarter 2018 net income of $36.7 million or $0.34 per diluted share, compared to net income of $5.5 million or $0.05 per diluted share in the second quarter of 2017. Second quarter 2018 operating earnings(1) was $59.5 million or $0.54 per diluted share, compared to $23.7 million or $0.22 per diluted share in the second quarter of 2017.
NGHCP NGHCO NGHCN NGHC NGHCZ

 
National General Holdings Corp. Announces Dividends on Common and Preferred Stock

2018-08-06 globenewswire
NEW YORK, Aug. 06, 2018 (GLOBE NEWSWIRE) -- National General Holdings Corp. (NASDAQ:NGHC) today announced that its Board of Directors approved quarterly dividends on the company's common and preferred stock as follows:
NGHCP NGHCO NGHCN NGHC NGHCZ

 
Insurers Set for Q2 Earnings on Aug 6: BHF, AEL, NGHC, ARGO

2018-08-03 zacks
The second-quarter earnings season has crossed the halfway mark with 381 members of the elite S&P 500 index having already reported their financial numbers. Per the latest Earnings Preview, the performance of these index participants indicates a 25% increase in total earnings on 10.4% higher revenues. The beat ratio is impressive with 80.1% companies surpassing bottom-line expectations while 73.8% outperforming on the top-line front.
AGIIL NGHCP BHF NGHCO NGHCN CY ARGO ARGO NGHC AGII NGHCZ

 
National General Holdings Corp. to Announce 2018 Second Quarter Results on August 6, 2018

2018-07-18 globenewswire
NEW YORK, July 18, 2018 (GLOBE NEWSWIRE) -- National General Holdings Corp. (NASDAQ:NGHC) announced today that it plans to release 2018 second quarter results after the market closes on Monday, August 6, 2018. At 9:30 AM ET on Tuesday, August 7, 2018, Chief Executive Officer Barry Karfunkel and Chief Financial Officer Mike Weiner will review results and discuss business conditions via a conference call that may be accessed as follows:
NGHCP NGHCO NGHCN NGHC NGHCZ

1
A.M. Best Revises Torchmark's (TMK) Outlook, Affirms Ratings

2018-07-12 zacks
Credit rating giant A.M. Best has revised the outlooks for Torchmark Corporation (TMK - Free Report) and its units. The rating agency has affirmed the Long-Term Issuer Credit Ratings (Long-Term ICR) of “a-” and the Long and Short-Term Issue Credit Ratings (Long-Term IR and Short-Term IR) for Torchmark. Simultaneously, A.M. Best revised the outlook for the abovementioned ratings from stable to negative.
NGHCP TMK NGHCO NGHCN FAF NGHC TMK NGHCZ

1
Milder Hurricane Forecast Bring Respite to Insurers: 4 Picks

2018-07-11 zacks
A recent report by Insurance Information Institute stated that the 2018 Atlantic hurricane season is expected to be milder than the earlier forecast. This is a relief for insurers since they faced above-average catastrophe activity in 2017 and incurred billions in losses from claim costs.
NGHCP NGHCO GJT NGHCN PGR XL ACGL NGHCZ ALL NGHC XLGLF ARHPF CNFR

2
The AmTrust Buyout Could Be a No-Lose Deal for Investors

2018-07-06 investorplace
Shares of commercial insurer AmTrust (NASDAQ:AFSI) were scheduled to open Jul. 3 at $14.60 per share, despite having been approved for sale to private equity at $14.75 per share.
NGHCP NGHCO MHLA NGHCN MHLD NGHC AFSI NGHCZ

2
A.M. Best Assigns “A-” (Excellent) Rating and Stable Outlook to Insurance Subsidiaries of AmTrust Financial Services, Inc.

2018-07-03 globenewswire
NEW YORK, July 03, 2018 (GLOBE NEWSWIRE) -- AmTrust Financial Services, Inc. (Nasdaq:AFSI) (“AmTrust” or the “Company”) announced today that A.M. Best has removed AmTrust’s rating from under review with negative implications, and assigned AmTrust’s insurance subsidiaries a Financial Strength Rating of “A-” (Excellent) with a Stable outlook.
NGHCP NGHCO MHLA NGHCN AFSS AFST NGHCZ MHLD NGHC AFSI

27
AmTrust Stockholders Approve Amended Merger Transaction

2018-06-21 globenewswire
NEW YORK, June 21, 2018 (GLOBE NEWSWIRE) -- AmTrust Financial Services, Inc. (Nasdaq:AFSI) ("AmTrust" or the "Company") announced today that, based on a certified vote tally from the Special Meeting held today, AmTrust stockholders have approved the proposed amended merger transaction in which Evergreen Parent, L.P., an entity formed by private equity funds managed by Stone Point Capital LLC ("Stone Point"), together with Barry Zyskind, Chairman and CEO of AmTrust, George Karfunkel and Leah Karfunkel (collectively, the "Karfunkel-Zyskind Family"), will acquire the approximately 45% of the Company's issued and outstanding common shares that the Karfunkel-Zyskind Family and certain of its affiliates and related parties do not presently own or control.
NGHCP NGHCO MHLA NGHCN AFSS AFST NGHCZ MHLD NGHC AFSI

27
Leading Proxy Advisory Firm ISS Recommends AmTrust Stockholders Vote “FOR” Amended Merger Agreement with Evergreen Parent

2018-06-12 globenewswire
NEW YORK, June 11, 2018 (GLOBE NEWSWIRE) -- AmTrust Financial Services, Inc. (Nasdaq:AFSI) (the "Company" or "AmTrust") today announced that leading independent proxy advisory firm Institutional Shareholder Services, Inc. (“ISS”) has recommended that AmTrust stockholders vote “FOR” the Company’s amended merger agreement with Evergreen Parent, L.P., an entity formed by the Karfunkel-Zyskind Family and private equity funds managed by Stone Point Capital LLC (“Stone Point”), at the upcoming Special Meeting of Stockholders on June 21, 2018.
NGHCP NGHCO MHLA NGHCN AFSS AFST NGHCZ MHLD NGHC AFSI

27
AmTrust Financial Services, Inc. Appoints J. Daniel Hickey Group Chief Underwriting Officer

2018-06-11 globenewswire
NEW YORK, June 11, 2018 (GLOBE NEWSWIRE) -- AmTrust Financial Services, Inc. (Nasdaq:AFSI) (the “Company” or “AmTrust”) today announced that J. Daniel Hickey has taken on the role of Group Chief Underwriting Officer.
NGHCP NGHCO MHLA NGHCN AFSS AFST NGHCZ MHLD NGHC AFSI

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

CUSIP: 636220808